Skip to main navigation
Skip to main content
Skip to Footer
Global
Sandoz Site Directory
Our Work
What We Do
Disease Areas
Prescription Medicines
Over-The-Counter Medicines
Partnerships and Collaborations
Biopharmaceuticals
About Us
Who We Are
Corporate Responsibility
Doing Business Responsibly
Investor Information
Contact Us
Diversity & Inclusion
News
All News
Media Releases
Publications
Media Library
Stay Up-To-Date
Media Contacts
Careers
Job Search
Working at Sandoz
Search
All News
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Featured News
Media Releases
In the News
Filter By
2022
May
Media Release
/
May 12, 2022
Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio
Read More
April
Media Release
/
Apr 26, 2022
Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook
Read More
Media Release
/
Apr 14, 2022
Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio
Read More
Media Release
/
Apr 06, 2022
Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
Read More
March
Media Release
/
Mar 14, 2022
Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce
Read More
February
Media Release
/
Feb 18, 2022
Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
Read More
Media Release
/
Feb 02, 2022
Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021
Read More
2021
December
Media Release
/
Dec 22, 2021
Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA
Read More
Media Release
/
Dec 20, 2021
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
Read More
October
Media Release
/
Oct 26, 2021
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
Read More
Search Results Navigation
Current page
1
of 5
Page
2
of 5
Page
3
of 5
Page
4
of 5
Page
5
of 5
…
Next page
next ›
Last page
last »
Twitter
Tweet
Facebook
Share
Share
Twitter
Facebook
LinkedIn
Email
Whatsapp
Jump to Comments
Print
Save
You are here
Home
›
News
›